dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic doxazosin erection cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold.

APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription doxazosin erection oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand doxazosin erection Cardura® and Carduran® , doxazosin erection an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin erection to be marketed as Cardura® XL.It doxazosin erection an alpha blocker used to treat high blood pressure doxazosin erection benign prostatic doxazosin erection February 22, 2005, the US FDA approved a sustained release form of doxazosin erection to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood.

onlyRoutes oralDoxazosin mesylate, doxazosin erection quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® Cardura®.